[go: up one dir, main page]

WO1996040042A3 - Stabilized steroid compositions - Google Patents

Stabilized steroid compositions Download PDF

Info

Publication number
WO1996040042A3
WO1996040042A3 PCT/US1996/009651 US9609651W WO9640042A3 WO 1996040042 A3 WO1996040042 A3 WO 1996040042A3 US 9609651 W US9609651 W US 9609651W WO 9640042 A3 WO9640042 A3 WO 9640042A3
Authority
WO
WIPO (PCT)
Prior art keywords
metal
degradation
conditions
steroid compositions
stabilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1996/009651
Other languages
French (fr)
Other versions
WO1996040042A2 (en
Inventor
Chong Min Won
Christianna L Strohbeck
Sheng-Yuh Tang
Bih-Hsiung Hsu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Rhone Poulenc Rorer Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Pharmaceuticals Inc filed Critical Rhone Poulenc Rorer Pharmaceuticals Inc
Priority to AU61641/96A priority Critical patent/AU6164196A/en
Priority to BR9608721-8A priority patent/BR9608721A/en
Priority to EP96919250A priority patent/EP0843548A4/en
Priority to JP9501925A priority patent/JPH11507359A/en
Publication of WO1996040042A2 publication Critical patent/WO1996040042A2/en
Publication of WO1996040042A3 publication Critical patent/WO1996040042A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Colloid Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The degradation of triamcinolone acetonide in aqueous solutions is studied under accelerated storage conditions of 70 °C over the pH range 1-10. Trace level metal ions can markedly accelerate the oxidative degradation in neutral and basic solutions, but pH conditions and/or the inclusion of metal-sequestering agents, such as ethylenediamine tetra acetate (EDTA), in a preparation depresses the metal catalysis.
PCT/US1996/009651 1995-06-07 1996-06-05 Stabilized steroid compositions Ceased WO1996040042A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU61641/96A AU6164196A (en) 1995-06-07 1996-06-05 Stabilized steroid compositions
BR9608721-8A BR9608721A (en) 1995-06-07 1996-06-05 Pharmaceutical composition and process for treating inflammation
EP96919250A EP0843548A4 (en) 1995-06-07 1996-06-05 Stabilized steroid compositions
JP9501925A JPH11507359A (en) 1995-06-07 1996-06-05 Stabilized steroid composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48533995A 1995-06-07 1995-06-07
US08/485,339 1995-06-07

Publications (2)

Publication Number Publication Date
WO1996040042A2 WO1996040042A2 (en) 1996-12-19
WO1996040042A3 true WO1996040042A3 (en) 1997-02-06

Family

ID=23927770

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/009651 Ceased WO1996040042A2 (en) 1995-06-07 1996-06-05 Stabilized steroid compositions

Country Status (6)

Country Link
EP (1) EP0843548A4 (en)
JP (1) JPH11507359A (en)
AU (1) AU6164196A (en)
BR (1) BR9608721A (en)
CA (1) CA2223385A1 (en)
WO (1) WO1996040042A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6315985B1 (en) 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
NZ556376A (en) * 2005-02-25 2010-01-29 Chiesi Farma Spa Pharmaceutical aerosol formulations for pressurized metered dose inhalers comprising a sequestering agent
EP2125822B1 (en) 2006-12-21 2014-11-19 Nerviano Medical Sciences S.R.L. Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
EP3456314A1 (en) 2017-09-14 2019-03-20 Tiofarma B.V. Topical formulation comprising 17-ketolic corticosteroid

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364617A (en) * 1990-04-26 1994-11-15 The Procter & Gamble Company Chelator compositions comprising oxime compounds
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4344940A (en) * 1981-11-30 1982-08-17 E. R. Squibb & Sons, Inc. Steroid formulation containing dipotassium EDTA
KR950000032A (en) * 1993-06-09 1995-01-03 류경열 How to make sesame oil

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5364617A (en) * 1990-04-26 1994-11-15 The Procter & Gamble Company Chelator compositions comprising oxime compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0843548A4 *

Also Published As

Publication number Publication date
JPH11507359A (en) 1999-06-29
WO1996040042A2 (en) 1996-12-19
BR9608721A (en) 1999-10-13
EP0843548A4 (en) 1998-10-28
CA2223385A1 (en) 1996-12-19
AU6164196A (en) 1996-12-30
EP0843548A2 (en) 1998-05-27
MX9709431A (en) 1998-10-31

Similar Documents

Publication Publication Date Title
AU2550895A (en) Room temperature sterilant
IE840378L (en) Detergent compositions
CA2180648A1 (en) Aqueous topical anti-acne compositions of low ph
CA2229271A1 (en) Compositions containing hydroxy acids or retinoids
EP0129283A3 (en) Improved penetrating topical pharmaceutical compositions containing corticosteroids
EP0911039A3 (en) Drug-resin complexes stabilized by chelating agents
AU3598793A (en) Aqueous stripping composition containing a peroxide and butyrolactone, ethylene carbonate or a water soluble ester
TW327125B (en) Composition and method for protecting against pine exhausted
NZ329184A (en) Delivery device for mixing and/or topically applying two compositions, one containing an active compound and the other containing a skin permeation enhancer
CA2164050A1 (en) Cosmetic compositions containing betulinic acid
WO2000015179A3 (en) Cosmetic composition
AU2941900A (en) Biodegradable cellulose acetate constructions and tobacco filter
CA2139381A1 (en) Guar as drift control agent
CA2166062A1 (en) The use of non-ionic surfactants in stable topical retinoid compositions
NZ333357A (en) Reduction of cardiotoxicity of an antitumor agent using manganese compound
ES8705220A1 (en) Cosmetic emulsion and method for making the same.
AU2922797A (en) Novel steroid nitrite and nitrate ester derivatives useful as anti-inflammatory drugs
CA2205943A1 (en) Corrosion inhibitor
WO1996040042A3 (en) Stabilized steroid compositions
EP0260869A3 (en) Deodorant composition
UA37187C2 (en) aqueous solution of methylolguidantoins, substantially anhydrous composition methylolguidantoins and method for preparation thereof, mixture containing liquid medium favorable<tab>for microbes growth, method for decelaration of microbes growth
MX9800194A (en) Nonaqueous detergent compositions comprising effervescent systems.
EP0810251A3 (en) Storage-stable one-component air activated formulations of polythiol and polyene employing iron compound
EP0914828A3 (en) Use of des-aspartate-angiotensin I
CA2165494A1 (en) Composition and method for inhibiting coal oxidation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: JP

Ref document number: 1997 501925

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/1997/009431

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2223385

Country of ref document: CA

Ref country code: CA

Ref document number: 2223385

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996919250

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1996919250

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996919250

Country of ref document: EP